The Natural History of COPD

Chronic Obstructive Pulmonary Disease

Volumn , Issue , 2008, Pages 115-123

  Vestbo, Jørgen ^a,b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Airways infections; Dutch hypotheses; Hypothesis; Hypoxaemia; Respiratory symptoms

Indexed keywords

EID: 84889615429     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470755976.ch10     Document Type: Chapter

References (79)

1. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001;17:982-94.
2. Rijcken B, Britton J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir Mon 1998;7:74-83.
3. Kerstjens HAM, Rijcken B, Schouten JP, Postma DS. Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax 1997;52:820-7.
4. Larson RK, Barman ML, Kueppers F, Fudenberg HH. Genetic and environmental determinants of chronic obstructive pulmonary disease. Ann Intern Med 1970;72:627-32.
5. Kueppers F, Miller RD, Gordon H, Hepper NG, Offord K. Familial prevalence of chronic obstructive pulmonary disease in a matched pair study. Am J Med 1977;63:336-42.
6. Cohen BH, Ball WC Jr, Brashears S et al. Risk factors in chronic obstructive pulmonary disease (COPD). Am J Epidemiol 1977;105:223-32.
7. Silverman EK, Chapman HA, Drazen JM et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease: risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998;157:1770-8.
8. Barker DJ, Godfrey KM, Fall C et al. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. BMJ 1991;303:671-5.
9. Stein CE, Kumaran K, Fall CH et al. Relation of fetal growth to adult lung function in south India. Thorax 1997;52:895-9.
10. Prescott E, Lange P, Vestbo J and the Copenhagen City Heart Study Group. Socio-economic status, lung function, and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J 1999;13:1109-14.
11. Prescott E, Vestbo J. Socioeconomic status and chronic obstructive pulmonary disease. Thorax 1999;54:737-41.
12. Hanrahan JP, Tager IB, Segal MR et al. The effect of maternal smoking during pregnancy on early infant lung function. Am Rev Respir Dis 1992;145:1129-35.
13. Carlsen HCL, Jaakkola JJK, Nafstad P, Carlsen K-H. In utero exposure to cigarette smoking influences lung function at birth. Eur Respir J 1997;10:1774-9.
14. Gold DR, Wang X, Wypij D et al. Effects of cigarette smoking on the pulmonary function in adolescent boys and girls. N Engl J Med 1996;335:931-7.
15. Le Souëf PN. Tobacco related lung diseases begin in childhood. Thorax 2000;55:1063-7.
16. Tager IB, Ngo L, Hanrahan JP. Maternal smoking during pregnancy: effects on lung function during the first 18 months of life. Am J Respir Crit Care Med 1995;152:977-83.
17. Gold DR, Tager IB, Weiss ST, Tosteson TD, Speizer FE. Acute lower respiratory illness in childhood as a predictor of lung function and chronic respiratory symptoms. Am Rev Respir Dis 1989;140:877-84.
18. Shaheen SO, Barker DJ, Shiell AW et al. The relationship between pneumonia in early childhood and impaired lung function in late adult life. Am J Respir Crit Care Med 1994;149:616-9.
19. Sherrill DL, Lebowitz MD, Knudson RJ, Burrows B. Smoking and symptom effects on the curves of lung function growth and decline. Am Rev Respir Dis 1991;144:17-22.
20. Gauderman WJ, Avol E, Gilliland F et al. The effect of air pollution on lung development from 10 to 18 years of age. N Engl J Med 2004;351:1057-67.
21. Lange P. Development and prognosis of chronic obstructive pulmonary disease with special reference to the role of tobacco smoking. Dan Med Bull 1992;39:30-48.
22. Lange P, Groth S, Nyboe J et al. Effects of smoking and changes in smoking habits on the decline of FEV1. Eur Respir J 1989;2:811-6.
23. Cook DG, Strachan DP. Summary of parental smoking on the effects of parental smoking on the respiratory health of children and implications for research. Thorax 1999;54:357-66.
24. Jaakkola MS. Environmental tobacco smoke and respiratory diseases. Eur Respir Mon 2000;15:322-83.
25. Royal College of Physicians of London. Health or Smoking? Follow-up report of the Royal College of Physicians. London: Pitman, 1983.
26. Camilli AE, Burrows B, Knudson RJ, Lyle SK, Lebowitz MD. Longitudinal changes in forced expiratory volume in one second in adults. Am Rev Respir Dis 1987;135:794-9.
27. Anthonisen NR, Connett JE, Kiley JP et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994;272:1497-505.
28. Anthonisen NR, Connett JE, Murray RP, for the Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002;166:675-9.
29. Hendrick DJ. Occupation and chronic obstructive pulmonary disease. Thorax 1996;51:947-55.
30. Kauffmann F, Drouet D, Lellouch J, Brille D. Occupational exposure and 12-year spirometric changes among Paris area workers. Br J Ind Med 1982;39:221-32.
31. Becklake MR. Occupational exposures: evidence for a causal association with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;140:S85-91.
32. Heederik D. Epidemiology of occupational respiratory diseases and risk factors. Eur Respir Mon 2000;15:429-47.
33. Krzyzanowski M, Jedrychowski W, Wysocki M. Factors associated with the change in ventilatory function and the development of chronic obstructive pulmonary disease in a 13-year follow-up of the Cracow study. Am Rev Respir Dis 1986;134:1011-9.
34. Korn RJ, Dockery DW, Speizer FE, Ware JH, Ferris BG Jr. Occupational exposures and chronic respiratory symptoms: a population-based study. Am Rev Respir Dis 1987;136:298-304.
35. Heederik D, Pouwels H, Kromhout H, Kromhout D. Chronic non-specific lung disease and occupational exposures estimated by means of a job exposure matrix: the Zutphen Study. Int J Epidemiol 1989;18:382-9.
36. Humerfelt S, Gulsvik A, Skjærven R et al. Decline in FEV1 and airflow limitation related to occupational exposures in men of an urban community. Eur Respir J 1993;6:1095-103.
37. Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987;70:171-9.
38. Lange P, Parner J, Vestbo J, Jensen G, Schnohr P. A 15-year follow-up of ventilatory function in adults with asthma. N Engl J Med 1998;339:1194-200.
39. Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004;126:59-65.
40. Lange P, Ulrik CS, Vestbo J, for the Copenhagen City Heart Study Group. Mortality in adults with self-reported bronchial asthma: a study of the general population. Lancet 1996;347:1285-9.
41. Wouters EFM. A wasting disease. In: Voelkel NF, MacNee W, eds. Chronic Obstructive Lung Disease. Hamilton, London: BC Dekker, 2002.
42. Agusti AG, Noguera A, Sauleda J et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-60.
43. Agusti AG, Sauleda J, Miralles C et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:485-9.
44. Burge PS, Calverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
45. Spencer S, Calverley PM, Burge PS, Jones PW, on behalf of the ISOLDE Study Group. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:122-8.
46. Mapel DW, Hurley JS, Frost FJ et al. Health care utilization in chronic obstructive pulmonary disease: a case-control study in a health maintenance organization. Arch Intern Med 2000;160:2653-8.
47. Zielinski J, MacNee W, Wedzicha W et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997;52:43-7.
48. Incalzi RA, Fuso L, De Rosa M et al. Comorbidity contributors to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2794-800.
49. Anthonisen NR, Wright EC, Hodking JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:14-20.
50. Hansen EF, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:1267-71.
51. Weitzenblum E, Hirth C, Ducolone A et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981;36:752-8.
52. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1856-61.
53. Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12.
54. Fletcher CM, Peto R, Tinker CM, Speizer FE. The Natural History of Chronic Bronchitis and Emphysema. Oxford: Oxford University Press, 1976.
55. Fletcher CM, Peto R. The natural history of chronic airflow obstruction. BMJ 1977;I:1645-8.
56. Annesi I, Kauffmann F. Is respiratory mucus hypersecretion really an innocent disorder? Am Rev Respir Dis 1986;134: 688-93.
57. Vollmer WM, McCamant LE, Johnson LR, Buist AS. Respiratory symptoms, lung function, and mortality in a screening center cohort. Am J Epidemiol 1989;129:1157-69.
58. Speizer FE, Fay ME, Dockery DW, Ferris BG Jr. Chronic obstructive pulmonary disease mortality in six US cities. Am Rev Respir Dis 1989;140(Suppl):S49-55.
59. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. The relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 1990;45:579-85.
60. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995;8:1333-8.
61. Sherman CB, Xu X, Speizer FE et al. Longitudinal lung function decline in subjects with respiratory symptoms. Am Rev Respir Dis 1992;46:855-9.
62. Vestbo J, Prescott E, Lange P, and the Copenhagen City Heart Study Group. Association of chronic mucus hypersecretion with FEV1 decline and COPD morbidity. Am J Respir Crit Care Med 1996;153:1530-5.
63. Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002;166:329-32.
64. Lange P, Parner J, Prescott E, Vestbo J. Chronic bronchitis in an elderly population. Age Ageing 2003;32:636-42.
65. Kanner RE, Anthonisen NR, Connett JE, for the Lung Health Study Research Group. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:358-64.
66. Donaldson GC, Seemungal TAR, Bhomik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
67. Anthonisen NR. The British hypothesis revisited. Eur Respir J 2004;23:657-8.
68. Orie NGM, Sluiter HJ, de Vries K, Tammeling GJ, Witkop J. The host factor in bronchitis. In: Orie NGM, Sluiter HJ, eds. Bronchitis: an International Symposium. Assen, Netherlands: Royal van Gorcum, 1961.
69. Vestbo J, Prescott E. An update on the Dutch hypothesis and chronic respiratory disease. Thorax 1998;53(Suppl 2):S15-9.
70. Postma DS, Boezen HM. Rationale for the Dutch hypothesis: allergy and airway hyperresponsiveness as genetic factors and their interaction with environment in the development of asthma and COPD. Chest 2004;126:96-104S.
71. Hospers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP. Histamine airway hyperresponsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000;356:1313-7.
72. Vestbo J, Hansen EF. Airway hyperresponsiveness and COPD mortality. Thorax 2001;56(Suppl 2):11-4.
73. Rijcken B, Scouten JP, Xu X, Rosner B, Weiss ST. Bronchial hyperresponsiveness to histamine is associated with accelerated decline of FEV1. Am J Respir Crit Care Med 1995;151:1377-82.
74. Villar MT, Dow L, Coggon D, Lampe FC, Holgate ST. The influence of increased bronchial responsiveness, atopy, and serum IgE on decline in FEV1: a longitudinal study in the elderly. Am J Respir Crit Care Med 1995;151:656-62.
75. Parker DR, O'Connor GT, Sparrow D, Segal MR, Weiss ST. The relationship of non-specific airway responsiveness and atopy to the rate of decline of lung function: the normative aging study. Am Rev Respir Dis 1990;141:589-94.
76. O'Connor GT, Sparrow D, Weiss ST. A prospective study of methacholine airway responsiveness as a predictor of pulmonary function decline: the Normative Aging Study. Am J Respir Crit Care Med 1995;152:87-92.
77. Tashkin DP, Altose MD, Connett JE et al. for the Lung Health Study Research Group. Methacholine reactivity predicts chages in lung function over time in smokers with early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:1802-11.
78. Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic airways obstruction in a sample of the general population. N Engl J Med 1987;317:1309-14.
79. Kondoh Y, Taniguchi H, Yokoyama S et al. Emphysematous change in chronic asthma in relation to cigarette smoking: assessment by computed tomography. Chest 1990;97:845-9.